Piper Sandler raises Blackstone stock price target on fundraising By Investing.com

Piper Sandler raised Blackstone's price target to $130 from $122 while keeping a Neutral rating, citing strong fundraising and second-best quarterly fundraising since 2022. The firm trimmed 2026 and 2027 earnings estimates to $5.91 and $7.57, respectively, on expected pressure from softer fee-earning assets and real estate fees. Blackstone also reported Q1 2026 EPS of $1.36 versus $1.34 expected and revenue of $3.62 billion versus $3.41 billion expected, though broader capital markets activity may depend on resolution of the Iran conflict.

Analysis

The setup is less about a simple re-rating and more about duration: BX is increasingly being valued on the durability of fee-bearing AUM and the optionality of future monetizations, while near-term fee pressure is pushing the market to look through the next 2-3 quarters. If private markets and IPO windows reopen, even modest acceleration in realizations can re-ignite performance fees, which are disproportionately valuable because they fall through at very high incremental margins. That makes the stock a levered beneficiary of any broad risk-on turn in capital markets, but also means the multiple can compress quickly if exit markets stay shut.

The second-order winner is Blackstone’s fundraising franchise itself: persistent scale in secondaries and private wealth creates a flywheel where fundraising strength begets access to larger mandates, even when management fees are temporarily soft. Competitively, that pressures other alt managers with more cyclical AUM mixes and weaker distribution into a harder fight for allocations; BX can absorb a slower fee environment better because its platform breadth lets it shift emphasis toward products with more stable capital. The broader takeaway is that the market is increasingly paying for resilience in fundraising, not just current EPS, which helps explain why the stock can underperform on headline earnings while still attracting higher target multiples.

The main contrarian risk is that the current narrative may be over-discounting how long geopolitical uncertainty can suppress real transaction activity. If capital markets stay cautious into 2H26, management-fee softness can linger longer than consensus models, and the implied 22x 2026 DE multiple could prove fragile. Conversely, if Iran-related risk fades quickly, the market may re-rate BX before the earnings revisions fully bottom, creating an asymmetric upside window.

For trading, the cleanest expression is to buy BX on pullbacks with a 3-6 month horizon, using the recent estimate cuts as the entry point but targeting a rerating if deal activity stabilizes. A tighter expression is a call spread for the next 6-9 months to capture multiple expansion without overpaying for near-term volatility. Relative value favors long BX versus a more fee-sensitive alt manager basket if you expect the public markets/IPO reopening to benefit the best-capitalized platform first.

Key Decisions for Investors

• Long BX on weakness with a 3-6 month horizon; target a re-rating toward the low-130s if fundraising stays strong and transaction activity improves, with downside cushioned by the franchise quality but capped if fee pressure persists.
• Buy a 6-9 month BX call spread rather than stock outright to express reopening of IPO/M&A markets; this gives defined risk if capital markets remain shut longer than expected.
• Pair trade: long BX / short a fee-sensitive public markets or alt-manager basket over 1-2 quarters; thesis is that scale and fundraising mix should outperform peers as estimates keep drifting lower.
• Trim/add tactically around any escalation/de-escalation in Middle East risk; if geopolitical headlines begin to ease, expect BX multiple support to improve before fundamentals fully catch up.